Format

Send to

Choose Destination
See comment in PubMed Commons below
Oncotarget. 2012 Sep;3(9):998-1010.

Phenotypic screening reveals topoisomerase I as a breast cancer stem cell therapeutic target.

Author information

1
Section of Hematology/Oncology, Children's Hospital of Pittsburgh of UPMC, The University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Abstract

Cancer stem cells (CSCs) are a subpopulation generally thought to be responsible for cancer initiation and progression. Because CSCs are often rare in the total tumor cell population and differentiate rapidly when grown in culture, it has been challenging to uncover compounds that selectively target CSCs. We previously described CSC-emulating cells derived from breast cancer cell lines that maintained a stable undifferentiated state. We optimized a phenotypic assay with these cells and screened 1,280-bioactive compounds, identifying five that preferentially inhibited CSC-like cell proliferation. Using a compound-guided target identification approach, we found high topoisomerase I (Topo I) expression levels in breast CSC-like cells and primary breast CSCs. Structurally unrelated small molecules targeting Topo I preferentially inhibited CSC-like cells. These results illustrate the substantial power of this CSC phenotypic screening platform and promote Topo I as a potential molecular therapeutic target for therapies aimed at expunging CSCs.

PMID:
22948175
PMCID:
PMC3660065
DOI:
10.18632/oncotarget.632
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Impact Journals, LLC Icon for PubMed Central
    Loading ...
    Support Center